基本信息
views: 569
Career Trajectory
Bio
My own research is focused on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing non-invasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic.
Targeted therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. Critical to the development of this approach, is to determine which treatment is most likely to be benefit an individual patient. Currently, prostate-specific antigen (PSA) is the best routinely available biomarker providing diagnostic and prognostic information about prostate cancer. PSA testing is useful, but does not reliably determine whether or not a treatment is working, nor does not provide definitive guidance in selecting one therapy over another. My colleagues and I are evaluating promising new technologies to capture and characterize circulating tumor cells from a routine blood draw. We are finding that the number of circulating tumor cells in a patient’s blood helps determine a patient’s prognosis and whether or not a treatment is working. Circulating tumor cells are also providing a biological snapshot of an individual patient’s tumor, which may help determine the choice of therapy.
Targeted therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. Critical to the development of this approach, is to determine which treatment is most likely to be benefit an individual patient. Currently, prostate-specific antigen (PSA) is the best routinely available biomarker providing diagnostic and prognostic information about prostate cancer. PSA testing is useful, but does not reliably determine whether or not a treatment is working, nor does not provide definitive guidance in selecting one therapy over another. My colleagues and I are evaluating promising new technologies to capture and characterize circulating tumor cells from a routine blood draw. We are finding that the number of circulating tumor cells in a patient’s blood helps determine a patient’s prognosis and whether or not a treatment is working. Circulating tumor cells are also providing a biological snapshot of an individual patient’s tumor, which may help determine the choice of therapy.
Research Interests
Papers共 1121 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Samir Zaidi, Jooyoung Park,Joseph M Chan,Martine P Roudier,Jimmy L Zhao,Anuradha Gopalan,Kristine M Wadosky,Radhika A Patel,Erolcan Sayar,Wouter R Karthaus, D Henry Kates,Ojasvi Chaudhary,
Proceedings of the National Academy of Sciences of the United States of Americano. 28 (2024): e2322203121-e2322203121
JU open plusno. 4 (2024)
JU open plusno. 4 (2024)
Charlotte S. Walmsley,Philip Jonsson,Michael L. Cheng,Sean Mcbride, Christopher Kaeser, Herbert Alberto Vargas,Vincent Laudone,Barry S. Taylor,Rajya Kappagantula,Priscilla Baez,Allison L. Richards,Anne Marie Noronha,
NPJ PRECISION ONCOLOGYno. 1 (2024): 34-34
Christina M Lockwood,Jason D Merker, Elizabeth Bain, Caroline Compton, Robert L Grossman,Donald Johann,Frederick Jones,Gregory Jones, Matthew Kreifels, Suzanne LeBlang, Jerry S H Lee,John Lyle,
Clinical pharmacology and therapeutics (2024)
Andrew T Lenis,Vignesh Ravichandran, Samantha Brown,Syed M Alam,Andrew Katims,Hong Truong,Peter A Reisz, Samantha Vasselman,Barbara Nweji,Karen A Autio,Michael J Morris,Susan F Slovin,
Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
crossref(2023)
crossref(2023)
crossref(2023)
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 1139
#Citation: 108972
H-Index: 153
G-Index: 315
Sociability: 9
Diversity: 3
Activity: 143
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn